IP Library Granted Patent US 7,265,209
Granted Patent B2
US 7,265,209 · App. 11/477,572 · Granted Sep 4, 2007

CE7-specific chimeric T cell receptor

Assignee: City of Hope
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,265,209
App. No.
11/477,572
Granted
Sep 4, 2007
Kind
B2
Abstract

Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such cells for cellular immunotherapy of CE7+ neuroblastoma are disclosed. In one embodiment, the immune cell is a T cell and the cell surface protein is a single chain FvFc: ζ receptor where Fv designates the V H and V L chains of a single chain monoclonal antibody to CE7 linked by peptide, F c represents a hinge-C H 2-C H 3 region of a human IgG 1 , and ζ represents the intracellular signaling domain of the zeta chain of human CD3. DNA constructs encoding a chimeric T-cell receptor and a method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor are also disclosed.

Claims (1)

1. A CE7-specific chimeric T cell receptor comprising an intracellular signaling domain, a transmembrane domain and an extracellular domain, the extracellular domain comprising a CE7-specific receptor and wherein the CE7-specific chimeric T cell receptor comprises amino acids 21-631 of SEQ ID NO:2.

Continuity (3)
Division 1012019800 · Apr 11, 2002
Provisional Application 6028285900 · Apr 11, 2001
Related Publication 20060246548A1 · Nov 2, 2006